HLS Therapeutics Inc.

Latest

06:30 ET HLS Therapeutics Announces Q2 2020 Financial Results

Revenue of $12.6 million and Adjusted EBITDA of $4.8 million Increasing peak-year sales estimate for Vascepa to C$275-325 million Clozaril's Canadian patient count and sales in local currency...


Jul 30, 2020, 06:30 ET HLS Therapeutics to Host Q2 2020 Financial Results Conference Call

TORONTO, July 30, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 2020 financial results by press release at 6:30 a.m. Eastern Time on...


Jul 20, 2020, 16:30 ET HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa® (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price

CADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions. PMPRB notifies HLS that following PMPRB's review, Vascepa's introductory price...


Jun 19, 2020, 14:00 ET HLS Therapeutics Reports Annual Meeting Results

TORONTO, June 19, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces...


Jun 17, 2020, 06:30 ET HLS Therapeutics to Present at the Raymond James Human Health Innovation Conference

TORONTO, June 17, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces...


Jun 10, 2020, 06:30 ET HLS Therapeutics Confirms Annual Shareholders' Meeting

TORONTO, ON, June 10, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets,...


Jun 01, 2020, 17:00 ET HLS Therapeutics to Present at the Jefferies Virtual Healthcare Conference

TORONTO, June 1, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces...


Jun 01, 2020, 06:30 ET HLS Therapeutics to Become Distributor of the Saladax MyCare™ Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents

The MyCare Insite is a point-of-care (POC) device that uses just a single drop of blood to measure the most commonly used antipsychotic drugs in patients' blood The MyCare Psychiatry Clozapine Assay...


May 21, 2020, 16:07 ET HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa® (Icosapent Ethyl) against COVID-19

TORONTO, May 21, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces...


May 07, 2020, 06:30 ET HLS Therapeutics Announces Q1 2020 Financial Results

Revenue of $13.9 million, Adjusted EBITDA of $6.1 million and Cash from Operations of $5.3 million Launched Vascepa® in the Canadian market Vascepa added to Health Canada's Register of Innovative...


Apr 30, 2020, 06:30 ET HLS Therapeutics to Host Q1 2020 Financial Results Conference Call

TORONTO, April 30, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2020 financial results by press release at 6:30 a.m. Eastern Time on...


Mar 31, 2020, 07:30 ET HLS Therapeutics Comments on U.S. District Court Decision on Amarin Patents

TORONTO, March 31, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, comments on ...


Mar 19, 2020, 06:30 ET HLS Therapeutics Announces Fourth Quarter and Fiscal 2019 Financial Results

Revenue of $54.2 million, Adjusted EBITDA of $31.6 million and Cash from Operations of $26.4 million Received approval from Health Canada for Vascepa® to reduce the risk of cardiovascular events...


Feb 27, 2020, 16:00 ET HLS Therapeutics to Host Q4 and Fiscal 2019 Financial Results Conference Call

TORONTO, Feb. 27, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets,...


Jan 28, 2020, 06:30 ET HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl)

Vascepa to be available on or about February 18, 2020, supported by a national Cardiovascular salesforce Vascepa becomes the first and only Health Canada-approved medication for reducing...


Jan 23, 2020, 06:30 ET HLS Therapeutics Files New Drug Submission for PERSERIS® in Canada

If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia TORONTO, Jan. 23, 2020 /CNW/ - HLS Therapeutics...


Jan 06, 2020, 15:30 ET HLS Therapeutics Announces 8 Years of Data Protection for Vascepa®

Peak-year sales estimate increases to CAD$200-300 million, from CAD$150-250 million Commercial launch expected to take place in the mid-February 2020 timeframe Vascepa is the subject of numerous...


Dec 31, 2019, 13:00 ET HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular Events

Health Canada approval follows priority review for Vascepa Vascepa becomes the first and only HC-approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in the...


Nov 15, 2019, 06:30 ET HLS Therapeutics Reports on U.S. FDA Advisory Committee Recommendation for Vascepa

TORONTO, Nov. 15, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces...


Nov 07, 2019, 06:30 ET HLS Therapeutics Announces Q3 2019 Financial Results

Revenue of $13.4 million, Adjusted EBITDA of $8.0 million and Cash from Operations of $6.8 million Paid a quarterly dividend of C$0.05 per outstanding common share Subsequent to quarter-end, received ...


Oct 24, 2019, 06:30 ET HLS Therapeutics to Host Q3 2019 Financial Results Conference Call

TORONTO, Oct. 24, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets,...


Oct 17, 2019, 06:30 ET HLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO™

From a single drop of blood from the tip of a finger, Athelas One WBC System generates white blood cell counts and neutrophils percentages in minutes The device could help lower the most commonly...


Aug 08, 2019, 06:30 ET HLS Therapeutics Announces Q2 2019 Financial Results

Revenue of $13.6 million, Adjusted EBITDA of $8.1 million and Cash from Operations of $9.0 million Filed the New Drug Submission for Vascepa® with Health Canada after having been granted Priority...


Jul 25, 2019, 06:30 ET HLS Therapeutics to Host Q2 2019 Financial Results Conference Call

TORONTO, July 25, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets,...


Jun 21, 2019, 12:40 ET HLS Therapeutics Reports Annual Meeting Results

TORONTO, June 21, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held on June 21, 2019 in Toronto, Ontario. A...